Search details
1.
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.
Cell
; 185(3): 563-575.e11, 2022 02 03.
Article
in English
| MEDLINE | ID: mdl-35120664
2.
Integrative clinical genomics of advanced prostate cancer.
Cell
; 161(5): 1215-1228, 2015 May 21.
Article
in English
| MEDLINE | ID: mdl-26000489
3.
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
N Engl J Med
; 388(8): 719-732, 2023 02 23.
Article
in English
| MEDLINE | ID: mdl-36795891
4.
Author Correction: Tumour lineage shapes BRCA-mediated phenotypes.
Nature
; 577(7789): E1, 2020 01.
Article
in English
| MEDLINE | ID: mdl-31822847
5.
Integrative Clinical Genomics of Advanced Prostate Cancer.
Cell
; 162(2): 454, 2015 Jul 16.
Article
in English
| MEDLINE | ID: mdl-28843286
6.
Tumour lineage shapes BRCA-mediated phenotypes.
Nature
; 571(7766): 576-579, 2019 07.
Article
in English
| MEDLINE | ID: mdl-31292550
7.
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
Br J Cancer
; 130(1): 53-62, 2024 01.
Article
in English
| MEDLINE | ID: mdl-37980367
8.
Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients.
J Urol
; 209(5): 918-927, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36974724
9.
ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis.
Nature
; 546(7660): 671-675, 2017 06 29.
Article
in English
| MEDLINE | ID: mdl-28614298
10.
Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality.
Prostate
; 82(11): 1107-1116, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35538298
11.
Genomic correlates of clinical outcome in advanced prostate cancer.
Proc Natl Acad Sci U S A
; 116(23): 11428-11436, 2019 06 04.
Article
in English
| MEDLINE | ID: mdl-31061129
12.
Combining next-generation hormonal therapy with PARP inhibition in metastatic castration-resistant prostate cancer.
Lancet
; 402(10398): 266-267, 2023 07 22.
Article
in English
| MEDLINE | ID: mdl-37285866
13.
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.
N Engl J Med
; 375(5): 443-53, 2016 Aug 04.
Article
in English
| MEDLINE | ID: mdl-27433846
14.
Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.
Prostate
; 77(15): 1478-1488, 2017 Nov.
Article
in English
| MEDLINE | ID: mdl-28925066
15.
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
Invest New Drugs
; 35(6): 742-750, 2017 12.
Article
in English
| MEDLINE | ID: mdl-28281183
16.
Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
JAMA
; 318(9): 825-835, 2017 09 05.
Article
in English
| MEDLINE | ID: mdl-28873162
17.
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide.
Clin Cancer Res
; 30(6): 1111-1120, 2024 Mar 15.
Article
in English
| MEDLINE | ID: mdl-38226958
18.
Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy.
NPJ Precis Oncol
; 8(1): 34, 2024 Feb 14.
Article
in English
| MEDLINE | ID: mdl-38355834
19.
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.
Eur Urol
; 84(3): 253-256, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37087376
20.
Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer.
J Immunother Precis Oncol
; 6(4): 162-169, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-38143953